AstraZeneca scrapped multiple late-stage pipeline programs after disappointing efficacy, including shutting down atuliflapon, a FLAP inhibitor tested in a phase 2 asthma study. The company said it discontinued the trial due to efficacy and removed the program from its pipeline. The report also lists additional discontinued programs, including ALXN2420 for pituitary acromegaly and ANGPTL3 inhibitor AZD1705 as well as a siRNA program (AZD6912) earlier studied in healthy volunteers. Collectively, the actions narrow near-term life-cycle opportunities and suggest a more selective portfolio stance. Separately, the FDA proposed withdrawing Amgen’s Tavneos by alleging “untrue statements” in the approval application. The enforcement action would remove the small-molecule C5aR antagonist from the market if finalized.